(Q38104738)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23650954%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Osteoporosis treatment: why ibandronic acid? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23650954%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23650954%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Vidya Kunnathully

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23650954%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

davide gatti

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23650954%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

3

Silvano Adami

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23650954%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Giovanni Orsolini

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23650954%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

English

0 references

publication date

7 May 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23650954%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

29 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23650954%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23650954%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23650954%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

1371-1381

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23650954%20AND%20SRC:MED&resulttype=core&format=json

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

29 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Is the use of placebo controls ethically permissible in clinical trials of agents intended to reduce fractures in osteoporosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Efficacy and safety of ibandronate given by intravenous injection once every 3 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Sustained vertebral antifracture efficacy of oral anti-osteoporotic therapies in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Comparing non-vertebral fracture risk reduction with osteoporosis therapies: looking beneath the surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Ibandronate: a clinical pharmacological and pharmacokinetic update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Evidence of sustained vertebral and nonvertebral antifracture efficacy with ibandronate therapy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Effect of monthly ibandronate on hip structural geometry in men with low bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia-a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Oral ibandronate preserves trabecular microarchitecture: micro-computed tomography findings from the oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Oral ibandronate in postmenopausal osteoporotic women alters micromechanical properties independently of changes in mineralization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Determinants of bone turnover markers in healthy premenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Osteoporosis therapies: evidence from health-care databases and observational population studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Efficacy and safety of monthly ibandronate in men with low bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Treatment of osteoporosis after liver transplantation with ibandronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Fracture outcomes related to persistence and compliance with oral bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Determinants of adherence to osteoporosis treatment in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Medication persistence with weekly versus daily doses of orally administered bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Tolerability and compliance with risedronate in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

The kidney and bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Bisphosphonate nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Preclinical perspectives on bisphosphonate renal safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Duration of treatment for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Renal Safety and Pharmacokinetics of Ibandronate in Multiple Myeloma Patients With or Without Impaired Renal Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Long-Term Effects of Amino-Bisphosphonates on Circulating γδ T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.795949

10.1517/14656566.2013.795949

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23650954%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference